Lung Cancer CT Screening May Help to Detect Coronary Artery Disease
“Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal.”
Cancer Risk Declines in Old Age, New MSK Research Helps Explain Why
“When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer. That’s because genetic mutations build up in cells over years and decades, and ultimately drive the development of cancer. Now a study from researchers at Memorial Sloan Kettering Cancer Center (MSK) and their collaborators provides new evidence about how advanced age can also be protective against cancer. The study, conducted in a mouse model of lung cancer, was published in Nature on December 4.”
FDA approves durvalumab for limited-stage small cell lung cancer
“On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.”
Cambridge researchers develop urine test for early detection of lung cancer
“Cambridge scientists have developed a urine test for early detection of lung cancer. The test, the first of its kind, detects ‘zombie’ cells that could indicate the first signs of the disease.”
FDA Approves New Drug for Lung and Pancreatic Cancers
“The FDA has granted accelerated approval to zenocutuzumab, a new drug for adults with advanced non-small-cell lung cancer (NSCLC) or pancreatic cancer. The drug is the first comprehensive treatment approved for cancers with NRG1 fusion that have spread or that can’t be surgically removed and have worsened after previous treatments.”
Repurposed drug has promising efficacy in non-small cell lung cancer
“DALLAS – Dec. 09, 2024 – An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed. The findings, published in Clinical Cancer Research, a journal of the American Association for Cancer Research, could lead to new treatments for a major subset of lung cancer patients.”
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
“— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic non-small cell lung cancer (NSCLC).”
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
“The FDA granted this BTD based on data from the TROPION-Lung05 Phase II trial with supporting data from the TROPION-Lung01 Phase III trial. Results from a pooled analysis of patients with previously treated EGFRm NSCLC in these studies were presented this month at the European Society of Medical Oncology (ESMO) Asia 2024 Congress. This is the first BTD for datopotamab deruxtecan.”
Lung Cancer Research Foundation Announces 2024 Scientific Research Grant Awards
“NEW YORK, Dec. 10, 2024 /PRNewswire/ — The Lung Cancer Research Foundation® (LCRF) is pleased to announce its 2024 Scientific Grant Program awards, funding $3.55 million in new research, the largest single-year investment in its history. This year’s grant cycle includes awards in the following areas: LCRF Leading-Edge Grant in Lung Cancer, LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer, LCRF Research Grants on Understanding Resistance in Lung Cancer, LCRF Minority Career Development Award (CDA) for Lung Cancer, and the IASLC-LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers. Earlier this year, LCRF awarded the American Lung Cancer Screening Initiative (ALCSI), led by Chi-Fu Jeffrey Yang, MD, of Massachusetts General Hospital, a $320,000 grant to conduct its “Plus One” screening initiative and research study.”
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
“HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer.”
